Obseva SA (NASDAQ:OBSV) Short Interest Update

Obseva SA (NASDAQ:OBSV) was the recipient of a large decrease in short interest in September. As of September 15th, there was short interest totalling 1,230,000 shares, a decrease of 29.7% from the August 31st total of 1,750,000 shares. Based on an average daily volume of 883,800 shares, the days-to-cover ratio is presently 1.4 days. Currently, 3.7% of the shares of the stock are sold short.

A number of research firms have recently issued reports on OBSV. HC Wainwright reiterated a “buy” rating and issued a $36.00 price objective on shares of Obseva in a report on Wednesday, July 1st. SVB Leerink dropped their target price on Obseva from $7.00 to $5.00 and set an “outperform” rating for the company in a report on Tuesday, July 7th. Wedbush restated a “buy” rating and set a $30.00 target price on shares of Obseva in a report on Friday, August 14th. Zacks Investment Research cut Obseva from a “buy” rating to a “hold” rating in a report on Thursday, August 13th. Finally, BMO Capital Markets cut Obseva from an “outperform” rating to a “market perform” rating and dropped their target price for the company from $5.00 to $4.00 in a report on Monday, July 6th. One analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $13.25.

OBSV traded down $0.09 during midday trading on Thursday, reaching $2.39. 23,006 shares of the company’s stock traded hands, compared to its average volume of 759,782. The firm has a fifty day moving average of $2.74 and a two-hundred day moving average of $3.21. The stock has a market capitalization of $119.04 million, a price-to-earnings ratio of -1.00 and a beta of 0.84. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.52 and a quick ratio of 2.52. Obseva has a 52 week low of $1.63 and a 52 week high of $8.51.

Obseva (NASDAQ:OBSV) last announced its earnings results on Thursday, August 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.04. Sell-side analysts forecast that Obseva will post -1.62 EPS for the current year.

Several large investors have recently made changes to their positions in the company. Logos Global Management LP bought a new position in shares of Obseva in the 2nd quarter worth approximately $6,862,000. California Public Employees Retirement System bought a new position in shares of Obseva in the 2nd quarter worth approximately $401,000. Aigen Investment Management LP bought a new position in shares of Obseva in the 2nd quarter worth approximately $212,000. Cutter & CO Brokerage Inc. bought a new position in shares of Obseva in the 2nd quarter worth approximately $193,000. Finally, Virtu Financial LLC bought a new position in shares of Obseva in the 2nd quarter worth approximately $279,000. 48.54% of the stock is owned by hedge funds and other institutional investors.

About Obseva

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.

Recommended Story: Momentum Indicators

Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.